Stocks Health care XBIT
NASDAQ · Health careXBiotech Inc. (XBIT)
It posted a net loss of $45.1M. In fiscal 2025 capital spending exceeded operating cash flow by $40.2M. At June 30, 2026 it held $109.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about XBiotech Inc.
- Net worth
- XBiotech Inc. has a market value (market cap) of $58.2M at the latest share price, and shareholders' equity of $128.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2023 revenue was $0 (-100.0% year on year), with a net loss of $24.6M.
- Cash flow
- In fiscal 2025 operations used $39.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- XBiotech Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What XBiotech Inc. does
XBiotech Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XBIT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$45.5M | -$1.49 | -$40.2M |
| 2024 | n/a | -$38.5M | -$1.26 | -$32.3M |
| 2023 | $0 | -$24.6M | -$0.81 | -$19.1M |
| 2022 | $4M | -$32.9M | -$1.08 | -$15.4M |
| 2021 | $18.4M | -$17.4M | -$0.58 | $65.9M |
| 2020 | $44M | -$11.2M | -$0.36 | -$68.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Dividends
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2022 | n/a | $0 | n/a |
| 2021 | n/a | $75M | n/a |
| 2020 | n/a | $0 | n/a |
| 2019 | n/a | $0 | 0% |
Latest SEC filings
What XBiotech Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 2, 2026
- October 2, 2026Proxy statement DEF 14A
- August 13, 2026
- May 14, 2026
- April 29, 2026
- March 13, 2026
- March 11, 2026
- January 23, 2026Passive stake changed SCHEDULE 13G/A
- January 23, 2026Passive stake changed SCHEDULE 13G/A
- December 9, 2025
Insider trades
What the people running XBiotech Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns XBIT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| John Simard13G, passive | 17.7% | January 23, 2026 |
| W. Thorpe McKenzie13G, passive | 9.76% | January 23, 2026 |
Largest institutional holders
Insiders
Questions about XBIT
What does XBiotech Inc. do?
XBiotech Inc. is a company in the Health care sector, listed on NASDAQ as XBIT. Its shares trade on NASDAQ under the ticker XBIT.
What is XBiotech Inc.'s net worth?
XBiotech Inc. has a market value (market cap) of $58.2M at the latest share price, and shareholders' equity of $128.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is XBiotech Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $45.1M.
When did XBiotech Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the annual report to shareholders from October 2, 2026.
When is XBiotech Inc.'s next earnings report?
XBiotech Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare XBIT with
Follow XBIT
Get an email when XBiotech Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values XBiotech Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.